SCHEMBL5557320

SCHEMBL5557320

CN(C)c1cc(NC(=O)OC(C)(C)C)c(NC(=O)CC(=O)c2cccc(-c3ccncc3)c2)cc1C(F)(F)F

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 4/20 0.42
SCN5A Q14524 2/20 0.39
SCN9A Q15858 2/20 0.39
POLB P06746 2/20 0.38
AAK1 Q2M2I8 3/20 0.37
CSF1R P07333 1/20 0.36
KIT P10721 1/20 0.36
MGLL Q99685 1/20 0.35
AURKA O14965 2/20 0.34
RXFP1 Q9HBX9 1/20 0.34
LMNA P02545 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5557828 0.92 SCN5A (0.41) CYP17A1SCN5ASCN9APOLBCSF1R
SCHEMBL5557956 0.92 WNT3A (0.38) SCN5ASCN9APOLBAAK1
SCHEMBL5557264 0.91 CYP17A1 (0.40) CYP17A1SCN5ASCN9APOLBAAK1
SCHEMBL5563492 0.91 ABL1 (0.39) CYP17A1SCN5ASCN9APOLBAAK1
SCHEMBL5557099 0.90 POLB (0.38) CYP17A1POLBAAK1RXFP1LMNA
SCHEMBL5563764 0.89 ABL1 (0.41) SCN5ASCN9APOLBAAK1
SCHEMBL5563839 0.89 SCN9A (0.44) SCN5ASCN9APOLBCSF1RKIT
SCHEMBL5563095 0.89 CYP17A1 (0.44) CYP17A1SCN5ASCN9APOLBAAK1
SCHEMBL5562076 0.89 CYP17A1 (0.44) CYP17A1SCN5ASCN9APOLBAAK1
SCHEMBL5559923 0.88 CYP17A1 (0.44) CYP17A1SCN5ASCN9APOLBAAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474416-B1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS HOFFMANN LA ROCHE (CH) 2007-09-26 EP disclosed
EP-1651234-B1 COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS HOFFMANN LA ROCHE (CH) 2007-09-26 EP disclosed
US-6949542-B2 Dihydro-benzo[b][1,4]diazepin-2-one derivatives HOFFMAN-LA ROCHE INC. (US) 2005-09-27 US disclosed
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG (CH) 2003-09-04 US disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives CYP1B1, GRIN2B, CYP4B1 CYP17A1 942/4885SCN5A 303/4885SCN9A 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.